Pharmacological strategies for the management of comorbid
depression and schizophrenia

J 2020

Pharmacological strategies for the management of comorbid depression and schizophrenia

ČEŠKOVÁ, Eva

Základní údaje

Originální název

Pharmacological strategies for the management of comorbid depression and schizophrenia

Autoři

ČEŠKOVÁ, Eva (203 Česká republika, garant, domácí)

Vydání

EXPERT OPINION ON PHARMACOTHERAPY, Abingdon, TAYLOR & FRANCIS LTD, 2020, 1465-6566

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.889

Kód RIV

RIV/00216224:14740/20:00115688

Organizační jednotka

Středoevropský technologický institut

DOI

http://dx.doi.org/10.1080/14656566.2020.1717466

UT WoS

000509444600001

Klíčová slova anglicky

Depression; schizophrenia; antipsychotics; antidepressants; anti-inflammatory agents; biomarkers

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 3. 2021 18:30, Mgr. Pavla Foltynová, Ph.D.

Anotace

V originále

Introduction: Depressive symptoms may occur in any phase of schizophrenia and can have far-reaching consequences. Areas covered: The author focuses on recent reviews and meta-analyses dealing with the prevalence, importance, etiopathogenesis, and pharmacotherapy of comorbid depression and schizophrenia. Depressive symptoms in acute episodes may improve in parallel with psychosis due to antipsychotic treatment. Therefore, the first step is to evaluate the current antipsychotic treatment of psychotic symptoms and consider changing the dosage. A second step is switching antipsychotic medications, since there are indications that some medications are slightly more effective in reducing depressive symptoms than others. For persistent depressive episodes, additional therapeutic interventions are indicated. Most guidelines recommend the administration of antidepressants as an add-on treatment with a limited evidence level. Immunotherapeutic strategies could be successful, at least in some schizophrenia patients. Expert opinion: In the near future, precision psychiatry should enable clinicians to recognize specific biotypes with unique biosignatures that will guide accurate and prompt clinical management for individual patients.

Návaznosti

LQ1601, projekt VaV

Název: CEITEC 2020 (Akronym: CEITEC2020)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020

Citovat

ČEŠKOVÁ, Eva. Pharmacological strategies for the management of comorbid depression and schizophrenia. EXPERT OPINION ON PHARMACOTHERAPY. Abingdon: TAYLOR & FRANCIS LTD, 2020, roč. 21, č. 4, s. 459-465. ISSN 1465-6566. Dostupné z: https://dx.doi.org/10.1080/14656566.2020.1717466.

@article{1658197,
   author = {Češková, Eva},
   article_location = {Abingdon},
   article_number = {4},
   doi = {http://dx.doi.org/10.1080/14656566.2020.1717466},
   keywords = {Depression; schizophrenia; antipsychotics; antidepressants; anti-inflammatory agents; biomarkers},
   language = {eng},
   issn = {1465-6566},
   journal = {EXPERT OPINION ON PHARMACOTHERAPY},
   title = {Pharmacological strategies for the management of comorbid depression and schizophrenia},
   url = {https://www.tandfonline.com/doi/full/10.1080/14656566.2020.1717466},
   volume = {21},
   year = {2020}
}

TY  - JOUR
ID  - 1658197
AU  - Češková, Eva
PY  - 2020
TI  - Pharmacological strategies for the management of comorbid depression and schizophrenia
JF  - EXPERT OPINION ON PHARMACOTHERAPY
VL  - 21
IS  - 4
SP  - 459-465
EP  - 459-465
PB  - TAYLOR & FRANCIS LTD
SN  - 14656566
KW  - Depression
KW  - schizophrenia
KW  - antipsychotics
KW  - antidepressants
KW  - anti-inflammatory agents
KW  - biomarkers
UR  - https://www.tandfonline.com/doi/full/10.1080/14656566.2020.1717466
L2  - https://www.tandfonline.com/doi/full/10.1080/14656566.2020.1717466
N2  - Introduction: Depressive symptoms may occur in any phase of schizophrenia and can have far-reaching consequences. Areas covered: The author focuses on recent reviews and meta-analyses dealing with the prevalence, importance, etiopathogenesis, and pharmacotherapy of comorbid depression and schizophrenia. Depressive symptoms in acute episodes may improve in parallel with psychosis due to antipsychotic treatment. Therefore, the first step is to evaluate the current antipsychotic treatment of psychotic symptoms and consider changing the dosage. A second step is switching antipsychotic medications, since there are indications that some medications are slightly more effective in reducing depressive symptoms than others. For persistent depressive episodes, additional therapeutic interventions are indicated. Most guidelines recommend the administration of antidepressants as an add-on treatment with a limited evidence level. Immunotherapeutic strategies could be successful, at least in some schizophrenia patients. Expert opinion: In the near future, precision psychiatry should enable clinicians to recognize specific biotypes with unique biosignatures that will guide accurate and prompt clinical management for individual patients.
ER  -

ČEŠKOVÁ, Eva. Pharmacological strategies for the management of comorbid depression and schizophrenia. \textit{EXPERT OPINION ON PHARMACOTHERAPY}. Abingdon: TAYLOR \&{} FRANCIS LTD, 2020, roč.~21, č.~4, s.~459-465. ISSN~1465-6566. Dostupné z: https://dx.doi.org/10.1080/14656566.2020.1717466.

Podrobný výpis o publikaci